Background: Paclitaxel has been approved for 3-weekly administration in Japan. Recent reports suggest that weekly paclitaxel can achieve a higher tumor response and lower toxicity. Methods: This study was designed to investigate the usefulness and tolerability of weekly paclitaxel by 1-hour infusion in patients with metastatic breast cancer who were previously treated with docetaxel or other anticancer agents. Results: Thirty-five patients were enrolled. The overall response rate was 41.2% (14/34, 95% confidence interval: 24.6–59.3%). The median time to progression and the median survival time were 218.5 and 624 days, respectively. One patient developed dyspnea, probably induced by a hypersensitivity reaction. The most common hematological toxicities were leukopenia and neutropenia, although no patients developed grade 4 leukopenia or neutropenia and G-CSF support was not required. Conclusions: Weekly paclitaxel could be safely administered and achieved a relatively high response rate. Weekly paclitaxel would be a good candidate second-line therapy for recurrent or advanced breast cancer.

Smith RE, Brown AM, Mamounas EP, et al: Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26. J Clin Oncol 1999;17:3403–3411.
Seidman AD, Hudis CA, Albanel J, et al: Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 1998;16:3353–3361.
Untch M, Untch A, Seven BU, et al: Comparison of paclitaxel and docetaxel (taxotere) in gynecologic and breast cancer cell lines with the ATP-cell viability assay. Anticancer Drugs 1994;5:24–30.
Seidman AD, Hochhauser D, Gollub M, et al: Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: A phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. J Clin Oncol 1996;14:1877–1884.
Japanese Breast Cancer Society: General Rules for Clinical and Pathological Recording of Breast Cancer (13th version). Tokyo, Kanehara & Co. Ltd, 1998.
Hortobagyi GN: Treatment of breast cancer. N Engl J Med 1998;339:974–984.
Sikov WM, Akerley W, Strenger R, et al: Weekly high-dose paclitaxel in locally advanced and metastatic breast cancer: A BrUOG study. Semin Oncol 1999;26(suppl 18):6.
Marhenke D, Lick H-J, Scholz U., et al: Weekly paclitaxel for metastatic breast cancer (MBC) (abstract 016). 8th International Congress on Anti-Cancer Treatment, Paris, 1998.
Gori S, Mosconi AM, Basurtol C, et al: Weekly paclitaxel in metastatic breast cancer patients: A phase II study. Tumori 2002;88:470–473.
Sola C, Lluch A, Garcia-Conde J, et al: Phase II study of weekly paclitaxel (P) treatment in recurrent breast cancer after high-dose chemotherapy (HDC) (abstract 245). Proc Am Soc Clin Oncol 1999;18:65.
Perez EA, Vogel CL, Irwin DH, et al: Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol 2001;19:4216–4223.
Seidman AD, Berry D, Cirrincione C, et al: CALGB 9840: Phase III study of weekly (W) paclitaxel (P) via 1-hour (h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC (abstract 512). Proc Am Soc Clin Oncol 2004;22:14S.
Kimura M, Koida T, Yanagita Y: Weekly administration of paclitaxel for advanced or metastatic breast cancer – short-course premedications for outpatients. Jpn J Cancer Chemother 2001;27:1703–1708.
Emoto T, Yoshikawa K, Yoshioka Y, et al: Clinical study of weekly paclitaxel administration for metastatic breast cancer based on time to progression (TTP) and survival. Jpn J Cancer Chemother 2003;30:817–822.
Kim R, Osaki A, Toge T: Feasibility and therapeutic efficacy of weekly 1-h low-dose paclitaxel infusion for relapsed breast cancer. Oncol Rep 2003;10:145–150.
Breier S, Labedinsky C, Ayaviri C, et al: Long-term weekly paclitaxel over 1 hour infusion with de-escalated premedication. A phase II trial report. Breast Cancer Res Treat 1999;57:KA-W160A.
Mickiewicz E, Alvarez AM, Brosio C, et al: A promising second-line treatment with weekly Taxol (T) in anthracycline recurrent advanced breast cancer (ABC) patients (pts) (abstract 515). Proc Am Soc Clin Oncol 1999;18:135.
Scholz U, Luck HJ, Canzler U, et al: A phase I study. UFT/leucovorin combined with paclitaxel for anthracycline-pretreated advanced breast cancer. Oncology (Huntingt) 2000;14(suppl 9):44–46.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.